A Relative Bioavailability Study of Acetaminophen 650 mg Extended Release Gelcaps Under Fed Condition

• Status: Completed
• Trial end date: 2007-12-01
• Target enrollment: 0
• Participant gender: Male

Summary

The study was conducted as an open label, balanced, randomised, two-treatment, two-period, two-sequence, single dose, crossover bioavailability study comparing acetaminophen extended release gelcaps 650 mg (containing acetaminophen 650 mg) of OHM Laboratories Inc. with TYLENOLÒ arthritis pain caplets 650 mg (containing acetaminophen 650 mg) of McNeil Consumer & specialty Pharmaceuticals in healthy, adult, human, male subjects under fed condition.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Ranbaxy Laboratories Limited
• Treatments: Acetaminophen

Criteria

Inclusion Criteria:

• Were in the age range of 18-45 years.

• Were neither overweight nor underweight for the corresponding height as per the Life Insurance Corporation of India height/weight chart for non-medical cases.

• Had voluntarily given written informed consent to participate in this study.

• Were of normal health as determined by medical history and physical examination of the subjects performed within 21 days prior to the commencement of the study.

• Were non-vegetarian.

There was no deviation in this regard.

Exclusion Criteria:

• Had a history of hypersensitivity to acetaminophen or to any of the components of the formulation.

• Had a history of skin rashes, thrombocytopenia, urticaria or angioedema.

• Had a history of peptic ulcer.

• Had recent history of nausea and vomiting

• Showed any evidence of organ dysfunction or any clinically significant deviation from the normal, in physical or clinical determinations.

• Showed presence of disease markers of HIV 1 or 2, Hepatitis B or C viruses or syphilis infection.

• Showed presence of values which were significantly different from normal reference ranges defined and/or judged clinically significant for haemoglobin, total white blood cells count, differential WBC count or platelet count.

• Were positive for urinary screen testing of drugs of abuse (opiates or cannabinoids)

• Showed presence of values which were significantly different from normal reference ranges and/or judged clinically significant for serum creatinine, blood urea nitrogen, serum aspartate aminotransferase (AST), serum alanine aminotransferase (ALT), serum alkaline phosphatase, serum bilirubin, plasma glucose or serum cholesterol.

• Showed clinically abnormal chemical and microscopic examination of urine defined as presence of RBC, WBC (>4/HPF), epithelial cells (>4/HPF), glucose (positive) or protein (positive).

• Showed clinically abnormal ECG or Chest X-ray.

• Had a history of serious gastrointestinal, hepatic, renal, cardiovascular, pulmonary, neurological or haematological disease, diabetes or glaucoma.

• Had a history of any psychiatric illness, which might impair the ability to provide written informed consent.

• Were regular smokers who smoked more than 10 cigarettes daily or had difficulty abstaining from smoking for the duration of each study period.

• Had history of drug dependence or excessive alcohol intake on a habitual basis of more than 2 units of alcoholic beverages per day (1 unit equivalent to half pint of beer or 1 glass of wine or 1 measure of spirit) or had difficulty in abstaining for the duration of each study period.

• Used any enzyme modifying drugs within 30 days prior to Day 1 of this study.

• Participated in any clinical trial within 12 weeks preceding Day 1 of this study.

• Subjects who, through completion of this study, had donated and/or lost more than 350 mL of blood in the past 3 months.

There was no deviation in this regard.